Cargando…
Comprehensive evaluation of eight commercial SARS-CoV-2 IgG assays
Sensitivity and specificity of serological assays are key parameters for the accurate estimation of SARS-CoV-2 sero-prevalence. The aim of this study was to compare 8 readily available IgG antibody tests using a panel of well-defined serum samples of prepandemic and pandemic origin. A cross-reaction...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7983330/ https://www.ncbi.nlm.nih.gov/pubmed/33930691 http://dx.doi.org/10.1016/j.diagmicrobio.2021.115382 |
_version_ | 1783667883570626560 |
---|---|
author | Hönemann, Mario Lück, Christian Maier, Melanie Pietsch, Corinna Dietze, Nadine Berthold, Tom Encalada, Marco Vinicio Narvaez Grünewald, Thomas Neumeister, Volker Dalpke, Alexander Liebert, Uwe Gerd |
author_facet | Hönemann, Mario Lück, Christian Maier, Melanie Pietsch, Corinna Dietze, Nadine Berthold, Tom Encalada, Marco Vinicio Narvaez Grünewald, Thomas Neumeister, Volker Dalpke, Alexander Liebert, Uwe Gerd |
author_sort | Hönemann, Mario |
collection | PubMed |
description | Sensitivity and specificity of serological assays are key parameters for the accurate estimation of SARS-CoV-2 sero-prevalence. The aim of this study was to compare 8 readily available IgG antibody tests using a panel of well-defined serum samples of prepandemic and pandemic origin. A cross-reaction panel included samples of patients with recent infection with either of the endemic Coronaviruses 229E, NL63, HKU1, or OC43. Additionally, samples with high antibody levels against influenza virus, adenovirus, and during acute EBV infection were included. Previous infection with endemic coronaviruses caused a significant amount of cross-reactivity in two of the assays. In contrast, the confidence intervals for the assays of Abbott, DiaSorin, Euroimmun and Roche encompassed the value of 98% for samples with a previous endemic HCoV infection. For all assays, sensitivities were between 91.3% and 98.8%. Assay performance was independent of the usage of either nucleocapsid or spike proteins. |
format | Online Article Text |
id | pubmed-7983330 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-79833302021-03-23 Comprehensive evaluation of eight commercial SARS-CoV-2 IgG assays Hönemann, Mario Lück, Christian Maier, Melanie Pietsch, Corinna Dietze, Nadine Berthold, Tom Encalada, Marco Vinicio Narvaez Grünewald, Thomas Neumeister, Volker Dalpke, Alexander Liebert, Uwe Gerd Diagn Microbiol Infect Dis Article Sensitivity and specificity of serological assays are key parameters for the accurate estimation of SARS-CoV-2 sero-prevalence. The aim of this study was to compare 8 readily available IgG antibody tests using a panel of well-defined serum samples of prepandemic and pandemic origin. A cross-reaction panel included samples of patients with recent infection with either of the endemic Coronaviruses 229E, NL63, HKU1, or OC43. Additionally, samples with high antibody levels against influenza virus, adenovirus, and during acute EBV infection were included. Previous infection with endemic coronaviruses caused a significant amount of cross-reactivity in two of the assays. In contrast, the confidence intervals for the assays of Abbott, DiaSorin, Euroimmun and Roche encompassed the value of 98% for samples with a previous endemic HCoV infection. For all assays, sensitivities were between 91.3% and 98.8%. Assay performance was independent of the usage of either nucleocapsid or spike proteins. Elsevier Inc. 2021-08 2021-03-22 /pmc/articles/PMC7983330/ /pubmed/33930691 http://dx.doi.org/10.1016/j.diagmicrobio.2021.115382 Text en © 2021 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Hönemann, Mario Lück, Christian Maier, Melanie Pietsch, Corinna Dietze, Nadine Berthold, Tom Encalada, Marco Vinicio Narvaez Grünewald, Thomas Neumeister, Volker Dalpke, Alexander Liebert, Uwe Gerd Comprehensive evaluation of eight commercial SARS-CoV-2 IgG assays |
title | Comprehensive evaluation of eight commercial SARS-CoV-2 IgG assays |
title_full | Comprehensive evaluation of eight commercial SARS-CoV-2 IgG assays |
title_fullStr | Comprehensive evaluation of eight commercial SARS-CoV-2 IgG assays |
title_full_unstemmed | Comprehensive evaluation of eight commercial SARS-CoV-2 IgG assays |
title_short | Comprehensive evaluation of eight commercial SARS-CoV-2 IgG assays |
title_sort | comprehensive evaluation of eight commercial sars-cov-2 igg assays |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7983330/ https://www.ncbi.nlm.nih.gov/pubmed/33930691 http://dx.doi.org/10.1016/j.diagmicrobio.2021.115382 |
work_keys_str_mv | AT honemannmario comprehensiveevaluationofeightcommercialsarscov2iggassays AT luckchristian comprehensiveevaluationofeightcommercialsarscov2iggassays AT maiermelanie comprehensiveevaluationofeightcommercialsarscov2iggassays AT pietschcorinna comprehensiveevaluationofeightcommercialsarscov2iggassays AT dietzenadine comprehensiveevaluationofeightcommercialsarscov2iggassays AT bertholdtom comprehensiveevaluationofeightcommercialsarscov2iggassays AT encaladamarcovinicionarvaez comprehensiveevaluationofeightcommercialsarscov2iggassays AT grunewaldthomas comprehensiveevaluationofeightcommercialsarscov2iggassays AT neumeistervolker comprehensiveevaluationofeightcommercialsarscov2iggassays AT dalpkealexander comprehensiveevaluationofeightcommercialsarscov2iggassays AT liebertuwegerd comprehensiveevaluationofeightcommercialsarscov2iggassays |